Sangamo Therapeutics
SGMO
SGMO
129 hedge funds and large institutions have $31.1M invested in Sangamo Therapeutics in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
52% less call options, than puts
Call options by funds: $29K | Put options by funds: $60K
54% less capital invested
Capital invested by funds: $68.2M → $31.1M (-$37.1M)
Holders
129
Holding in Top 10
–
Calls
$29K
Puts
$60K
Top Buyers
| 1 | +$989K | |
| 2 | +$548K | |
| 3 | +$467K | |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$267K |
| 5 |
Goldman Sachs
New York
|
+$251K |
Top Sellers
| 1 | -$3.07M | |
| 2 | -$1.04M | |
| 3 | -$839K | |
| 4 |
State Street
Boston,
Massachusetts
|
-$800K |
| 5 |
D.E. Shaw & Co
New York
|
-$681K |